ACTN4 has a poor prognosis with high expression in six tumor types (GBMLGG, LGG, MESO, PAAD, LUAD, LAML) and a poor prognosis with low expression in two tumor types (KIPAN, KIRC) (Figure 6B). This evidence concerns the gene ACTN4 and neoplasm.